Table 1. Selected trials incorporating... | American Society of Hematology

Table 1.

Selected trials incorporating TKIs in the initial therapy of Ph⁺ ALL

Reference	N	Age, median [range]	Regimen	CMR rate, %	Allo-HCT rate, %	RFS rate, %	OS rate, %
Imatinib
45	80	48 [15-63]	Intensive chemotherapy	50 (day 63)	49	—	76 (1 y)
39	29	69 [61-83]	Corticosteroids	4	—	48 (1 y)	74 (1 y)
46	59	45 [20-66]	Intensive chemotherapy	—	72	39 (5 y)	38 (5 y)
9	169	42 [16-64]	Intensive chemotherapy	—	72	50 (4 y)	38 (4 y)
57	54	51 [17-84]	Intensive chemotherapy	45 (overall)	30	43 (5 y)	43 (5 y)
15	133	45 [21-59]	Intensive chemotherapy	23 (2 cycles)	65	—	46 (5 y)
15	135	49 [18-59]	Low-intensity chemotherapy	29 (2 cycles)	62	—	46 (5 y)
37	34	45 [24-57]	Intensive chemotherapy	—	44	46 (5 y)	51 (5 y)
25	92	10 [1.3-21]	Intensive chemotherapy	—	—	70 (5 y)	—
Dasatinib
19	53	54 [24-77]	Corticosteroids	15 (day 85)	42	22 (20 mo)	31 (20 mo)
47	72	55 [21-80]	Intensive chemotherapy	65 (overall)	17	44 (5 y)	46 (5 y)
16	97	44 [20-60]	Intensive chemotherapy	—	42	62 (3 y)	69 (3 y)
40	71	69 [55-83]	Low-intensity chemotherapy	24 (consolidation)	10	28 (5 y)	36 (5 y)
26	60	10.2* [1.5-27.6]	Intensive chemotherapy	—	32	60† (5 y)	86 (5 y)
Nilotinib
31	90	47 [17-71]	Intensive chemotherapy	77 (3 mo)	63	72 (2 y)	72 (2 y)
Ponatinib
17	37	51 [27-75]	Intensive chemotherapy	78 (overall)	24	—	80 (2 y)
41	44	68 [27-85]	Corticosteroids	61 (evaluable; 6 mo)	—	—	87.5 (1 y)

Reference	N	Age, median [range]	Regimen	CMR rate, %	Allo-HCT rate, %	RFS rate, %	OS rate, %
Imatinib
45	80	48 [15-63]	Intensive chemotherapy	50 (day 63)	49	—	76 (1 y)
39	29	69 [61-83]	Corticosteroids	4	—	48 (1 y)	74 (1 y)
46	59	45 [20-66]	Intensive chemotherapy	—	72	39 (5 y)	38 (5 y)
9	169	42 [16-64]	Intensive chemotherapy	—	72	50 (4 y)	38 (4 y)
57	54	51 [17-84]	Intensive chemotherapy	45 (overall)	30	43 (5 y)	43 (5 y)
15	133	45 [21-59]	Intensive chemotherapy	23 (2 cycles)	65	—	46 (5 y)
15	135	49 [18-59]	Low-intensity chemotherapy	29 (2 cycles)	62	—	46 (5 y)
37	34	45 [24-57]	Intensive chemotherapy	—	44	46 (5 y)	51 (5 y)
25	92	10 [1.3-21]	Intensive chemotherapy	—	—	70 (5 y)	—
Dasatinib
19	53	54 [24-77]	Corticosteroids	15 (day 85)	42	22 (20 mo)	31 (20 mo)
47	72	55 [21-80]	Intensive chemotherapy	65 (overall)	17	44 (5 y)	46 (5 y)
16	97	44 [20-60]	Intensive chemotherapy	—	42	62 (3 y)	69 (3 y)
40	71	69 [55-83]	Low-intensity chemotherapy	24 (consolidation)	10	28 (5 y)	36 (5 y)
26	60	10.2* [1.5-27.6]	Intensive chemotherapy	—	32	60† (5 y)	86 (5 y)
Nilotinib
31	90	47 [17-71]	Intensive chemotherapy	77 (3 mo)	63	72 (2 y)	72 (2 y)
Ponatinib
17	37	51 [27-75]	Intensive chemotherapy	78 (overall)	24	—	80 (2 y)
41	44	68 [27-85]	Corticosteroids	61 (evaluable; 6 mo)	—	—	87.5 (1 y)

CMR, complete molecular remission; OS, overall survival; RFS, relapse-free survival.

Mean value provided.

Event-free survival provided.